CPAYCorpay
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- $7.15Beat
- vs $6.74 expected on Nov 4
- Stock move on it
- +6.78%
- one session
- Typical move
- ±3.9%
- average over 2 reports
- Price
- $456.00
- −1.29% today · $25.7B cap
Past and upcoming reports
2
| Nov 4, 2026 | Sep 30, 2026 | Time not given | $6.74 | Beat$7.15 | +6.78% |
| Aug 5, 2026 | Jun 30, 2026 | Time not given | $6.56 | Beat$6.63 | +0.95% |
After the report
Aug 5, 2026 report
This covers the Aug 5, 2026 report. The Nov 4, 2026 numbers are in the table above.
Corpay beat second-quarter EPS estimates, but shares fell 1.33% two days later as earnings-quality risk remained unresolved.
Corpay reported $6.63 EPS for the quarter ended June 30, beating the $6.22 estimate by 6.59%. Guidance details were unavailable. shares closed at $392.99 on August 7, down $5.29, while leverage remained elevated at 2.95 debt-to-equity.
Reported against expected
BeatReported EPS was $6.63 versus a $6.22 estimate, a $0.41 or 6.59% beat, reported August 5 for the quarter ended June 30.
Guidance
No forward guidance figures or explicit guidance tone were provided in the payload.
How the stock reacted
The event-day and subsequent reaction-window percentages were unavailable. CPAY fell 1.33% to $392.99 on August 7, two days after reporting.
What changed
Reported EPS reached $6.63, $0.41 above consensus, while earnings-quality and leverage concerns remained flagged.
What the price now assumes
The 1.33% decline to $392.99 suggests limited immediate credit for the EPS beat despite a 23.89 trailing P/E.
What it means for the business
Maintain a constructive bias. upgrade only if next-quarter results again reconcile reported EPS with adjusted performance.
The next one to three months, as we saw it then
Better case35%
A repeat reported-EPS beat with cleaner reconciliation could support the existing growth thesis and analyst target range of $390 to $475.
Base case40%
The EPS beat supports the thesis, but absent guidance and with shares at $392.99, valuation may remain range-bound until the next quarterly report.
Worse case25%
Leverage of 2.95 debt-to-equity and recurring reconciliation issues could outweigh the recent beat and pressure the growth multiple.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Enter only after next-quarter reported EPS again beats consensus with improved earnings reconciliation. no trade if guidance remains unavailable and the reconciliation issue persists.
Scenario odds are a judgement, not measured.